What GLOW is
GLOW is a name sellers use, not a drug name. It's sold as GLOW, a vial holding GHK-Cu, BPC-157 and TB-500. None of the documents behind this page mentions GLOW, so none of them says how much of each peptide a vial holds. Your vial's label is what counts. The amounts in this page's worked example are only an example.
GHK-Cu is a small peptide bound to copper. GHK is three amino acids, glycine, histidine and lysine, and a 2008 paper describes GHK-Cu as the complex GHK forms with a copper ion. A 2015 paper says GHK is present in human plasma, saliva and urine. Both papers list Skin Biology as their authors' affiliation, and this page takes from them only what the substance is. None of the documents this page rests on gives a molecular weight or a formula for GHK-Cu, so this page doesn't either.
FDA's review of BPC-157 says it's reported to be a peptide of 15 amino acids. It gives the formula of the free base as C62H98N16O22 and its molecular weight as 1419.5 g/mol, and describes the free base as a white to off-white lyophilized powder.
FDA's review of TB-500 says the free base is reported to be a synthetic fragment of thymosin beta-4, seven amino acids long, from amino acids 17 to 23 with an acetyl group on the first one. It gives the formula as C38H68N10O14 and the molecular weight as 889.01 g/mol.
Both reviews raise the names themselves. FDA says BPC-157 and TB-500 are common names, and that it has encountered multiple salts and derivatives, including different active moieties, sold commercially under the same common name.
Where it stands with the FDA
No FDA document behind this page reviews these three peptides together. FDA's two reviews each cover one peptide, and neither mentions GHK-Cu. They do mention BPC-157 and TB-500 together. The BPC-157 review notes websites that market products holding both. The TB-500 review says a search of the reports FDA collects about food, dietary supplements and cosmetics retrieved two cases about "blended TB-500 and BPC-157", and that the reports did not include safety assessments.
The BPC-157 review also describes an adverse event report about a product containing BPC-157 and TB500, used under the skin and labeled for "research purposes only". The patient developed diffuse hyperpigmentation and gingival darkening, and identical reactions when the product was used again. FDA says the events were likely due to the drug product, but that because the product contained two peptides it is not possible to assess a potential relationship between BPC-157 and what was reported. What follows is where each peptide stands on its own.
FDA says neither BPC-157 nor TB-500 is a component of any FDA-approved drug. Both reached the FDA because they were nominated for compounding. The nominations were later withdrawn, and FDA reviewed both on its own initiative. Neither name appears on FDA's list of nominated substances as updated May 14, 2026.
FDA reviewed BPC-157 for one use, ulcerative colitis. It concluded that the criteria weigh against putting BPC-157 on the list of substances pharmacies may compound with, and proposed not adding it. The reasons it gives include that BPC-157 isn't well characterized and that there's a lack of information on its safety profile and immunogenicity risks. FDA says it found no studies that gave BPC-157 to humans by four of the routes the nominations proposed, which are by mouth, under the skin, in the nose and through the skin. It identified two studies that gave it as a rectal enema for a maximum of two weeks, and says there is insufficient clinical safety information to characterize the safety profile of BPC-157. It also says it's concerned about the potential for immunogenicity of BPC-157 in an injectable dosage form.
FDA reviewed TB-500 for one use, wound healing. It reached the same conclusion and proposed not adding TB-500 to the list. FDA says it's particularly concerned about the absence of human data on drug products containing TB-500 given by any route, and that peptides given by injection may pose a significant risk for immunogenicity.
Each review reports the injection its own nominations described. The nominations for BPC-157 described an injection under the skin at 2,000 mcg/mL, among other forms. The nomination for TB-500 described a 3 mg/mL lyophilized powder for injection under the skin or into muscle. Each is the strength of a product of that one peptide.
FDA's meeting page lists both for discussion by its Pharmacy Compounding Advisory Committee on July 23, 2026. The meeting page had no minutes posted as of October 2026, so this page doesn't report a vote.
GHK-Cu is at a different stage. FDA's list of nominated substances, updated May 14, 2026, has an entry that reads "GHK-Cu (except for injectable routes of administration)" in category 1, which is the list's name for substances under evaluation. The list says the entry was removed from category 1 on April 22, 2026, because the nominations for GHK-Cu were withdrawn by the nominators. On May 5, 2026, one of them clarified that it meant to withdraw only its nomination for the injectable route, and FDA said the entry would be added back. So the entry FDA lists as under evaluation leaves injectable routes out. FDA has announced that it intends to consult the committee about GHK-Cu before the end of February 2027. Its announcement is current as of April 15, 2026, which is before the nominations were withdrawn, and its agenda lists GHK-Cu without naming a route. It said the time and location would be scheduled in the coming months, and it still read that way when this page was checked in October 2026.
Each of the three has a row in the same table on FDA's page about substances that may present significant safety risks, current as of April 22, 2026. The table lists substances that were previously in category 2, where FDA put substances that may present significant safety risks, and were withdrawn by their nominators. For BPC-157 and for TB-500 it says compounded drugs containing them may pose risk for immunogenicity for certain routes of administration. The GHK-Cu row is "GHK-Cu (for injectable routes of administration)", and it says compounded injectable drugs containing it may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans to inform safety-related considerations.
Storing GLOW
None of the documents behind this page says how to store a vial that holds all three, or how long one keeps once it's mixed. None gives a storage temperature for GHK-Cu.
For BPC-157 and TB-500, FDA's reviews repeat storage figures reported elsewhere, each for one substance on its own. Their conclusions say that as reported in the literature, BPC-157 is expected to be stable under storage conditions below -18°C and BPC-157 acetate below -20°C. They say TB-500 free base is reported to be stable below -20°C under reported storage conditions, which are sealed storage, away from moisture and light, under nitrogen, and TB-500 acetate below -15°C, protected from light and kept in a tightly closed container.
The reviews also repeat reported figures for how long BPC-157 and TB-500 free base keep in solution. Each is for one peptide alone, and the reviews cite a seller's product page and a product data sheet for them, so this page doesn't repeat them.
Both reviews also say that how stable a peptide stays depends heavily on how the finished product was made.
GLOW dosage calculator questions
How do I turn a GLOW dose into syringe units?
Pick the peptide your dose is of, divide that dose by that peptide's concentration to get millilitres, then multiply by 100. The same draw carries the others along in proportion. A vial with 5 mg of GHK-Cu, 5 mg of BPC-157 and 5 mg of TB-500 mixed with 2 mL holds 2.5 mg/mL of GHK-Cu, 2.5 mg/mL of BPC-157 and 2.5 mg/mL of TB-500, so ten units hold 250 mcg of GHK-Cu, 250 mcg of BPC-157 and 250 mcg of TB-500.
How much bacteriostatic water goes in a GLOW vial?
There's no single right amount. The water sets the concentration of every peptide in the vial at once, and changes none of the amounts. Choose the amount that puts your dose somewhere between about 10 and 40 units, where it's easiest to read.
Is GLOW approved by the FDA?
None of the FDA documents behind this page mentions GLOW or reviews these three peptides together. FDA says neither BPC-157 nor TB-500 is a component of any FDA-approved drug, and in the reviews it wrote for its July 2026 committee meeting it proposed not adding either to the list of substances pharmacies may compound with. On FDA's May 14, 2026 list, GHK-Cu is under evaluation by non-injectable routes only, and the nominations covering injections were withdrawn.
Does this page tell me how much GLOW to take?
No. None of the documents this page rests on describes a vial holding these three peptides, so there's no official dose of the blend to point to. The dose box is empty until you fill it in, and the chart only converts.
What's in a GLOW vial?
GLOW is a seller's name. It's sold as GLOW, a vial holding GHK-Cu, BPC-157 and TB-500. No document behind this page mentions it, so none of them says how much of each a vial holds. Read your vial's label and type the milligrams of each peptide into its own box. The amounts in this page's examples are only examples.
Why does the calculator ask which peptide the dose is of?
Because one draw carries all three. The peptides are dissolved in the same water, so setting the amount of one sets the amounts of the others, in the proportion they're in the vial. Pick the peptide your dose is of, and the table under the answer shows how much of the other peptides the same draw holds.
Has the FDA reviewed BPC-157 and TB-500 as a blend?
Not in the documents behind this page. FDA reviewed each on its own for its July 2026 committee meeting and proposed not adding either to the list of substances pharmacies may compound with. Its TB-500 review says a search of the reports FDA collects about food, dietary supplements and cosmetics retrieved two cases about "blended TB-500 and BPC-157", and that the reports did not include safety assessments. Its BPC-157 review describes one adverse event report about a product containing both, and says the events were likely due to the drug product, but that with two peptides in it a relationship to BPC-157 can't be assessed.
Is GHK-Cu for injection under FDA evaluation?
Not on FDA's May 14, 2026 list. The nominations to compound GHK-Cu for injection were withdrawn, and the entry FDA lists as under evaluation leaves injectable routes out. FDA's safety page says compounded injectable drugs containing GHK-Cu may pose risk for immunogenicity due to the potential for aggregation and peptide-related impurities, and that there are limited data in humans.
More peptide calculators by name
The same instrument, set up one peptide at a time. For any other vial, use the peptide reconstitution calculator.